Catalent
Catalent is a global CDMO providing drug development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, injectables, and consumer health, serving pharma, biotech, and wellness companies from 45+ facilities worldwide. Privately held by Novo Holdings A/S since December 2024.
- Company typePrivate
- Founded1933
- HeadquartersTampa, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Catalent does
Catalent is a global Contract Development and Manufacturing Organization (CDMO) serving pharmaceutical, biotechnology, and consumer health companies across the full drug lifecycle, from early-stage development through commercial manufacturing and clinical supply. The company's portfolio spans oral dose (including RP Scherer Softgel, OptiForm, spray drying, and micronization technologies), biologics (GPEX cell line development, SMARTag bioconjugation, OneBio integrated suite), cell therapy (autologous/allogeneic CAR-T, iPSC-derived therapies via the RheinCell platform, NK cells), gene therapy (UpTempo AAV and plasmid DNA manufacturing at commercial scale), specialty (inhalation, small molecule injectables), clinical supply services (OneHub portal, FastChain demand-led supply, FlexDirect direct-to-patient, CTSuccess planning), and self-care/consumer health (OTC, supplements, beauty). Catalent operates from more than 45 facilities across North America, Europe, Asia Pacific, and Latin America, with notable campuses at Harmans, Maryland (gene therapy), Princeton (cell therapy), Kansas City (biologics analytical and clinical supply), Morrisville/RTP (inhalation), Madison (mammalian cell line), and Gosselies, Belgium (cell therapy and plasmid DNA).
The business model is B2B professional services revenue earned through contract development, manufacturing, and supply agreements — quote-based pricing determined by project scope, complexity, scale, and contract length, with multi-year terms for commercial manufacturing and project-based engagement for clinical work. Catalent commercializes a set of proprietary technology platforms (GPEX, UpTempo, SMARTag, OptiForm, OneBio, iPSC, Qai) that differentiate its offering versus pure-play contract manufacturers. The company sells directly to enterprise customers through technical sales, scientific consultation, and strategic partnership agreements, supported by industry conference participation and thought leadership content. Approximately 2,400 of its ~15,000 employees are scientists and technicians.
Catalent was acquired by Novo Holdings A/S for $16.5 billion in December 2024, taking it private after years as a publicly traded NYSE-listed company under ticker CTLT. Ownership has shifted strategic emphasis toward fill-finish and prefilled syringe capacity for GLP-1 therapies, while the business has simultaneously undergone restructuring in cell and gene therapy — including layoffs at the Harmans, Maryland gene therapy plant and the announced closure of the Gosselies, Belgium cell therapy site — and has faced FDA regulatory scrutiny at the Catalent Indiana fill-finish facility that has delayed customer approvals. Leadership includes CEO Alessandro Maselli and CFO Matti Masanovich.
Catalent firmographics
Firmographics- Name
- Catalent
- Legal name
- Catalent, Inc.
- Website
- https://catalent.com
- Company type
- Private
- Founded year
- 1933
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Catalent is a global CDMO providing drug development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, injectables, and consumer health, serving pharma, biotech, and wellness companies from 45+ facilities worldwide. Privately held by Novo Holdings A/S since December 2024.
- Ownership category
- akta.pro rank
Catalent industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Cell Therapy CDMO (HLAGABAD), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)
Keywords
Where Catalent is headquartered
LocationHeadquarters
- HQ city
- Tampa
- HQ country
- United States
- HQ region
- North America
Offices14 records
Markets served
Catalent business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Catalent generates revenue through providing integrated CDMO services including drug substance manufacturing, drug product manufacturing, fill-finish services, clinical supply services, and commercial manufacturing. Services are provided on a project basis with long-term contracts for commercial manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based CDMO services with custom pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Catalent product offering
Product offeringCore offering
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that provides integrated pharmaceutical development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, specialty, and consumer health modalities. The company partners with pharma, biotech, and self-care innovators from early-stage development through commercial manufacturing, leveraging proprietary technology platforms such as GPEx, UpTempo, SMARTag, OptiForm, and iPSC. Services span drug substance and drug product manufacturing, fill-finish, clinical packaging and supply, regulatory support, and tech transfers across a network of 45+ facilities globally.
Product overview
Catalent is a leading global Contract Development and Manufacturing Organization (CDMO) offering an integrated portfolio of pharma services organized around five core business units: Pharma Services (oral dose, biologics, specialty), Clinical Supply Services, and Self-Care/Consumer Health. The Pharma Services unit includes oral dosage development and manufacturing via OptiForm Solution Suite and Softgel Technologies; biologics development through OneBio Suite combining GPEx cell line development, drug substance manufacturing, and drug product fill-finish; and cell/gene therapy manufacturing leveraging iPSC, UpTempo plasmid DNA, and SMARTag bioconjugation platforms. Clinical Supply Services provides end-to-end clinical trial support including FastChain demand-led supply, FlexDirect direct-to-patient distribution, CTSuccess planning, and Case Management for advanced therapies, accessible through the OneHub digital portal. Specialty services cover inhalation and small molecule injectables. Qai represents the company's first enterprise AI deployment for quality management.
Differentiator
Problem solved
Functional benefit
Brands
- OptiForm Total Supply: Integrated development, manufacturing and clinical supply solution combining formulation, clinical manufacturing, forecasting, packaging, labeling, storage and distribution.
- OneHub Portal
- FastChain Demand Led Supply
- FlexDirect
- CTSuccess
- OptiForm Solution Suite
- OneBio Suite
- GPEx
- SMARTag
- UpTempo
- Qai
- OneXpress Solution
- OptiDose Design Solution
- Portfolio Accelerator
Products and services
- Pharma Services Integrated CDMO solutions spanning oral dose, biologics, specialty and clinical supply. Services include tech transfers, commercial manufacturing, and regulatory support for pharmaceutical and biotech innovators.
- Oral Dose Comprehensive oral dosage solutions including development, bioavailability enhancement, dose form design, manufacturing and analytical services for tablets, capsules, softgel, and orally disintegrating formats.
- Biologics End-to-end biologics development and manufacturing including cell line development, process development, drug substance and drug product manufacturing, and analytical services.
- Cell Therapy GMP manufacturing and development services for autologous and allogeneic cell therapies including CAR-T, NK cells, and iPSC-derived cell products, with commercial-scale manufacturing capabilities.
- Gene Therapy Viral vector manufacturing and development services for AAV, lentiviral vectors, and gene therapies, including plasmid DNA manufacturing, process development, and GMP commercial manufacturing.
- Clinical Supply Services Global clinical supply management including packaging, labeling, storage, distribution, cold chain services, and comparator sourcing for Phase I-IV clinical trials.
- Self-Care (Consumer Health) Contract manufacturing for OTC products, dietary supplements, and beauty/personal care products including formulation, manufacturing, and packaging services.
- Specialty (Inhalation and Injectables) Specialized delivery solutions including inhalation products (dry powder inhalers, nasal delivery) and small molecule injectables with advanced containment technologies.
- OptiForm Total Supply Integrated development, manufacturing and clinical supply solution combining formulation, clinical manufacturing, forecasting, packaging, labeling, storage and distribution in a parallel approach.
- OneHub Portal Customer portal providing visibility into clinical supply operations including production timelines, inventory alerts, shipment tracking, and document management with secure sharing capabilities.
- FastChain Demand Led Supply Dynamic decentralized approach to secondary packaging, labeling and distribution of made-to-order patient kits based on actual site/patient demand with Pack to Stock, Pack to Order, and Hybrid models.
- FlexDirect Direct-to-Patient Services Clinical supply services enabling direct shipment of investigational products to patients' homes, reducing need for in-person site visits through site-to-patient and pharmacy-direct models.
- Case Management Services End-to-end supply chain coordination for cell and gene therapies including scheduling, shipment arrangement, chain of custody documentation, and 24/7 monitoring.
- CTSuccess Clinical Supply Planning Clinical supply planning service using proprietary StartScore methodology to evaluate project complexity and provide tailored support for study execution.
- Qai Enterprise AI-powered quality management tool integrating into existing quality workflows to accelerate root cause analysis, reduce repeat deviations, and improve reporting consistency across global manufacturing.
Companies that use Catalent
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Catalent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature9 records
Catalent partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- CarthericscoreExpanded agreement for iPSC-derived CAR-NK cell therapies, strengthening Catalent's position in cell therapy manufacturing services.
- Silexion TherapeuticscorePartnership for GMP clinical batch manufacturing of SIL204, next-generation siRNA therapy targeting mutated KRAS, at Catalent's facility in Limoges, France for Phase 2/3 trial in locally advanced pancreatic cancer.
- CarthericscoreExpanded partnership through amended commercial license agreement allowing Cartherics to use Catalent's cGMP-compliant iPSC line for manufacturing and commercializing CAR-NK cell therapies for cancer and endometriosis, including lead candidate CTH-401. Cartherics received FDA approval to use this cell line.
- GelMEDIXcoreGlobal partnership for development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Catalent provides GMP-compliant iPSC lines and manufacturing capabilities to support GelMEDIX's vision-restoring therapies through all clinical stages.
- S.BiomedicscoreStrategic partnership to develop and manufacture TED-A9, a cell therapy for Parkinson's disease. Catalent utilizes its global capabilities in cell therapy development and GMP manufacturing to support S.Biomedics' pipeline from early development through clinical trials and market launch.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Catalent competitors and assessment
Company assessmentDirect peers
- Lonza Group: Largest pure-play global CDMO offering biologics, cell & gene therapy, and small-molecule manufacturing across a comparable multi-modality footprint; competes head-to-head with Catalent in mammalian cell line, viral vector and oral dose services.
- Samsung Biologics: Korean large-mammalian biologics CDMO with massive single-site bioreactor capacity; competes directly with Catalent Biologics for mAb and recombinant protein programs from clinical through commercial supply.
- WuXi Biologics: Global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing; competes with Catalent's OneBio Suite and GPEx cell line offering, particularly for Asia-Pacific and cost-sensitive programs.
- Siegfried Holding: Swiss CDMO specializing in oral solid dose APIs and drug products; competes directly with Catalent's Oral Dose business in small-molecule formulation and manufacturing.
- Recipharm: European CDMO focused on oral solid dose, sterile fill-finish and biologics; competes with Catalent's European footprint across small-molecule and aseptic manufacturing services.
- PCI Pharma Services: Global CDMO focused on clinical trial supply, commercial packaging and sterile fill-finish; directly overlaps Catalent's Clinical Supply Services and specialty/injectables offerings.
- Vetter Pharma: Specialist CDMO for aseptic fill-finish of injectables and pre-filled syringes; directly competes with Catalent's sterile fill-finish and specialty injectable offerings, particularly for biologics and GLP-1 customers.
Broad incumbents
- Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest pharma services franchises globally via Patheon, covering drug substance, drug product, clinical supply and packaging; overlaps Catalent's integrated offering but sits within a much larger diversified life-sciences portfolio.
- IQVIA (Q² Solutions / Manufacturing Services): Diversified life-sciences services company with pharma manufacturing exposure through Q² Solutions and broader clinical/commercial services; partial overlap with Catalent's clinical supply and biologics analytics offerings.
Emerging players
- Charles River Laboratories: Primarily a CRO/preclinical services firm but expanding into cell & gene therapy CDMO via its CDMO segment; competes with Catalent's CGT offerings in early-stage and clinical manufacturing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Catalent social profiles
Digital presenceCatalent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Catalent leadership team
Management profileNumber of profiles
Profiles4 records
Catalent subsidiaries and ownership
Company hierarchySubsidiaries5 records
Catalent funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Catalent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Catalent
What does Catalent do?
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that provides integrated pharmaceutical development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, specialty, and consumer health modalities. The company partners with pharma, biotech, and self-care innovators from early-stage development through commercial manufacturing, leveraging proprietary technology platforms such as GPEx, UpTempo, SMARTag, OptiForm, and iPSC. Services span drug substance and drug product manufacturing, fill-finish, clinical packaging and supply, regulatory support, and tech transfers across a network of 45+ facilities globally.
Is Catalent a public or private company?
Catalent is a private company. It is classified as private equity controlled and is currently operating.
When was Catalent founded?
Catalent was founded in 1933. It employs 5,001 to 10,000 people.
Where is Catalent based?
Catalent is headquartered in Tampa, United States, in the North America region.
How does Catalent make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Catalent's main competitors?
Direct peers on record are Lonza Group, Samsung Biologics, WuXi Biologics, Siegfried Holding, Recipharm, PCI Pharma Services and Vetter Pharma. Broad incumbents are Thermo Fisher Scientific (Patheon CDMO) and IQVIA (Q² Solutions / Manufacturing Services). Charles River Laboratories is listed as an emerging player.
Does Catalent have an API?
No public API is recorded for Catalent.
What industry is Catalent in?
Catalent's product category is Pharmaceutical Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 3254 and its SIC code is 2834.